[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100482949":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":106,"collaborators":20,"id":108,"slug":20,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":20,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":20,"enrollmentInfo":116,"targetDuration":20,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":20,"overallStatus":24,"whyStopped":20,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"Verismo Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SynKIR-110","EXPERIMENTAL","Single dose gravity drip IV administration",[13],"Biological: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR","Autologous T cells Transduced with Mesothelin KIR-CAR",[9],null,[22,44,55,72,89],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Moffitt Cancer Center","RECRUITING","Tampa","Florida","33612","United States",{"type":30,"coordinates":31},"Point",[32,33],-82.45843,27.94752,{"lat":33,"lon":32},[36,41],{"name":37,"role":38,"phone":39,"phoneExt":20,"email":40},"Ashley O'Neil, MPH, LSSWB, CCRC","CONTACT","813-745-5240","Ashley.ONeil@moffitt.org",{"name":42,"role":43,"phone":20,"phoneExt":20,"email":20},"Ben Creelan, MD","PRINCIPAL_INVESTIGATOR",{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":28,"cosmosGeoPoint":50,"geoPoint":54,"contacts":20},"University of Kansas Cancer Center","ACTIVE_NOT_RECRUITING","Westwood","Kansas","66205",{"type":30,"coordinates":51},[52,53],-94.6169,39.04056,{"lat":53,"lon":52},{"facility":56,"status":24,"city":57,"state":58,"zip":59,"country":28,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"University of Pennsylvania","Philadelphia","Pennsylvania","19104",{"type":30,"coordinates":61},[62,63],-75.16362,39.95238,{"lat":63,"lon":62},[66,70],{"name":67,"role":38,"phone":68,"phoneExt":20,"email":69},"Andrea Standish","215-662-2419","andrea.standish@pennmedicine.upenn.edu",{"name":71,"role":43,"phone":20,"phoneExt":20,"email":20},"Janos Tanyi, MD, PhD",{"facility":73,"status":24,"city":74,"state":75,"zip":76,"country":28,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":30,"coordinates":78},[79,80],-95.36327,29.76328,{"lat":80,"lon":79},[83,87],{"name":84,"role":38,"phone":85,"phoneExt":20,"email":86},"Zheng Zhang","832-729-0975","ZZhang11@mdanderson.org",{"name":88,"role":43,"phone":20,"phoneExt":20,"email":20},"Mehmet Altan, MD",{"facility":90,"status":24,"city":91,"state":92,"zip":93,"country":28,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"University of Wisconsin Carbone Cancer Center","Madison","Wisconsin","53792",{"type":30,"coordinates":95},[96,97],-89.40123,43.07305,{"lat":97,"lon":96},[100,104],{"name":101,"role":38,"phone":102,"phoneExt":20,"email":103},"Cancer Connect","800-622-8922","CancerConnect@uwhealth.org",{"name":105,"role":43,"phone":20,"phoneExt":20,"email":20},"Zhubin Gahvari, MD",{"type":107,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100482949",false,"NCT05568680","SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma","A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma","Inclusion Criteria:\n\n* Pathologically confirmed recurrent or relapsed advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma (pleural or peritoneal) after at least 1 prior line of systemic therapy for advanced disease\n* Adult 18 years of age or older.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Has at least 1 measurable lesion by iRECIST for ovarian cancer or cholangiocarcinoma or lesions measurable for mRECIST for mesothelioma.\n* Satisfactory Blood coagulation parameters\n* Satisfactory organ and bone marrow function\n\nExclusion Criteria:\n\n* Active invasive cancers other than mesothelioma, cholangiocarcinoma, and ovarian unless surgically and medically cured without evidence of recurrent disease for 5 years.\n* History of T or B cell malignancies or previous gene-engineered T cell therapies.\n* Sarcomatoid\u002Fbiphasic mesothelioma.\n* Pulmonary exclusions\n* Have acquired hereditary, congenital immunodeficiency or have recognized immunodeficiency disease\n* Active hepatitis B, active hepatitis C, or any HIV infection at the time of screening\n* Active autoimmune disease","ALL","18 Years",{"count":117,"type":118},42,"ESTIMATED","INTERVENTIONAL",[121],"PHASE1","This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.",[124,125,126],"Ovarian Cancer","Cholangiocarcinoma Recurrent","Mesothelioma, Malignant","2026-06-23",{"date":129,"type":130},"2026-06-24","ACTUAL",{"date":132,"type":130},"2023-03-30",{"date":134,"type":118},"2027-12",{"name":5,"class":6},5]